DNA Vaccines: Induction of the immune response;Vacunas de ADN: Inducción de la respuesta inmunitaria

Salud Publica de Mexico

Volumn 51, Issue SUPPL.3, 2009, Pages

  Mota Sánchez, Javier ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

DNA; Immune response; Vaccines

Indexed keywords

DNA VACCINE;

ANIMAL; GENETICS; HUMAN; IMMUNITY; REVIEW;

ANIMALS; HUMANS; IMMUNITY; VACCINES, DNA;

EID: 77956990694     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342009000900012     Document Type: Article

References (30)

1. CDC. Achievements in Public Health, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48:243-248.
2. Kurstak E. Abstracts of the Third World Congress on Vaccines and Immunisation, WCVI 2002. Infections Control World Organization (ICWO) 2002;4-9:92.
3. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 2004;430:242-249.
4. World Health Organization. The World Health Report 2004. Geneve: World Health Organization, 2004.
5. Kurstak E. Towards the new global vaccinology era in prevention and control of diseases. Vaccine 2003;21:580-581.
6. Wilson CB, Marcuse EK. Vaccine safety--vaccine benefits: science and the public's perception. Nat Rev Immunol 2001;1:160-165.
7. Edwards KM, Decker MD. Combination vaccines: hopes and challenges. Pediatr Infect Dis J 1994;13:345-347.
8. Zepp F, Knuf M, Heininger U, Jahn K, Collard A, Habermehl P, et al. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 2004;22:2226-2233.
9. Zinka B, Rauch E, Buettner A, RueffF, Penning R. Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine 2006;24:5779-5780.
10. Reyes-Sandoval A, Ertl HC. DNA vaccines. Curr Mol Med 2001;1:217-243.
11. ShroffKE, Smith LR, Baine Y, Higgins TJ. Potential for plasmid DNAs as vaccines for the new millennium. Pharm Sci Technol Today 1999;2:205-212.
12. Giese M. DNA-antiviral vaccines: new developments and approaches: a review. Virus Genes 1998;17:219-232.
13. WolffJA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
14. Tang DC, Devit M, Johnson SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-154.
15. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
16. Waine GJ, McManus DP. Nucleic acids: vaccines of the future. Parasitol Today 1995;11:113-116.
17. Lewis PJ, Babiuk LA. DNA vaccines: a review. Adv Res 1999;94:129-188.
18. Babiuk LA, Babiuk SL, Loehr B, van Drunen Littel-van den Hurk S. Nucleic acid vaccines: research tools or commercial reality. Vet Immunol Immunopathol 2000;76:1-23.
19. Srivastava IK, Liu MA. Gene vaccines. Ann Intern Med 2003;138:550-559.
20. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000;68:793-806.
21. Kowalczyk DW, Ertl HC. Immune responses to DNA vaccines. Cell Mol Life Sci 1999;55:751-770.
22. Huygen K. Plasmid DNA vaccination. Microbes Infect 2005;7:932-938
23. Watts AM, Kennedy RC. DNA vaccination strategies against infectious diseases. Int J Parasitol 1999;29:1149-1163.
24. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003;21:649-658.
25. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001;19:2647-2656.
26. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001;1:209-219.
27. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008;8:108-120.
28. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008;9:776-788.
29. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007;25:2120-2127.
30. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, Conlon C, et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in IV-1-infected persons receiving combination antiretroviral therapy. Vaccine 2007;25:3277-3283.